Anticoagulation for secondary stroke prevention: another nail in the coffin?

Lancet Neurology

Volumn 6, Issue 2, 2007, Pages 97-99

  Elkind, Mitchell SV ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIPYRIDAMOLE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY OCCLUSION; BLEEDING; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

ANTICOAGULANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE;

EID: 33846217782     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70008-X     Document Type: Letter

References (10)

1. Oral anticoagulants (aimed INR 2.0-3.0) versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The ESPRIT Study Group. Lancet Neurol 6 (2007) 115-124
2. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42 (1997) 857-865
3. Mohr J., Thompson J., Lazar R., et al., for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
4. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke 29 (1998) 1389-1392
5. Chimowitz M., Lynn M., Howlett-Smith H., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005) 1305-1316
6. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
7. Sacco R., Prabhakaran S., Thompson J., et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 22 (2006) 4-12
8. Elkind M. Implications of stroke prevention trials: treatment of global risk. Neurology 65 (2005) 17-21
9. Gage B., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110 (2004) 2287-2292
10. Pullicino P., Thompson J., Barton B., Levin B., Graham S., and Freudenberger R. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 12 (2006) 39-46